https://nova.newcastle.edu.au/vital/access/ /manager/Index ${session.getAttribute("locale")} 5 https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:48700 Wed 29 Mar 2023 11:35:00 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:51503 Wed 28 Feb 2024 14:50:10 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:47737 Wed 25 Jan 2023 15:07:49 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:32080 Wed 24 Nov 2021 15:52:32 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:31068 Wed 24 Nov 2021 15:51:09 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:51839 Wed 20 Sep 2023 16:12:04 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:31003 Wed 19 Jan 2022 15:18:59 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:24377 1.5 fold in subjects with asthma, whereas, in healthy controls, only 14 entities were differentially expressed. Of the 168 genes that were changed in asthma, several biological processes were overrepresented, with 25 genes involved in "immune system processes". qPCR confirmed that S100P, S100A16, MAL and MUC1 were significantly increased in the asthma group post-meal. We also observed a strong correlation and a moderate correlation between the change in NLRP12 and S100A16 gene expression at 4 h compared to baseline, and the change in total and saturated non-esterified plasma fatty acid levels at 2 h compared to baseline. In summary, our data identifies differences in inflammatory gene expression that may contribute to increased airway neutrophilia following a high fat meal in subjects with asthma and may provide useful therapeutic targets for immunomodulation. This may be particularly relevant to obese asthmatics, who are habitually consuming diets with a high fat content.]]> Wed 17 Nov 2021 16:29:16 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:50107 Wed 12 Jul 2023 13:43:56 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:17148 Wed 11 Apr 2018 17:15:05 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:31124 Wed 11 Apr 2018 16:45:05 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:14520 Wed 11 Apr 2018 16:28:20 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:25338 s = 0.398, P = 0.015) and (r_s = 0.455, P = 0.005) respectively), with 1.7% greater absolute weight loss at week 10 corresponding to each one unit reduction in the asthma-related quality of life score at baseline. Furthermore, a lower baseline forced expiratory volume in 1 s/forced vital capacity correlated with greater weight loss (r_s = 0.398, P = 0.015). Male sex was associated with a 3.6 kg greater weight loss (P = 0.087). Reducing emotional eating during the programme was associated with greater weight loss in women (r_s = 0.576, P = 0.010). Conclusions This study demonstrates that individuals with more severe asthma at baseline are more successful in achieving weight loss, which could be a consequence of greater motivation and could be used as a motivational tool within the clinical setting. Gender tailoring of weight loss programmes may be useful to enhance weight loss success. Future studies are urgently needed to establish predictors of long-term weight loss maintenance in those with asthma. See Editorial, page 179 This study is the first to demonstrate that more severe asthma at baseline, male sex, and improvements in eating behaviours during weight loss are associated with greater weight loss success in overweight and obese adults with asthma. Our findings may inform the development of asthma-specific weight management guidelines.]]> Wed 11 Apr 2018 16:17:48 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:14698 Wed 11 Apr 2018 16:15:41 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:17057 Wed 11 Apr 2018 15:31:23 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:25152 Wed 11 Apr 2018 13:49:07 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:6954 Wed 11 Apr 2018 13:48:02 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:22588 Wed 11 Apr 2018 13:37:32 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:16765 Wed 11 Apr 2018 13:10:01 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:22224 Wed 11 Apr 2018 13:02:09 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:28242 Wed 11 Apr 2018 12:02:15 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:16779 Wed 11 Apr 2018 11:59:41 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:24115 Wed 11 Apr 2018 11:19:58 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:13797 Wed 11 Apr 2018 11:18:00 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:20997 n = 144) in a multicultural high school in Western Sydney completed the asthma symptoms ISAAC video questionnaire (AVQ3.0), spirometry and allergy skin prick tests. A dietitian administered a 'Food Frequency' and 'Food Habits' questionnaire and a dietary history interview. Results: Students who spoke a language other than English, consumed a traditional or mixed dietary pattern, with lower consumption of saturated fat, compared to students who spoke English only. Saturated fat intake increased and fibre intake decreased with length of time in Australia. Intake of foods high in saturated or trans fatty acids were positively associated with length of stay in Australia. No associations between nutrient intake or whole food intake and self-reported wheeze were observed. Conclusion: As time progressed, dietary intake of immigrant children changed. While this was not associated with the development of wheeze in the students in this cohort, these changes are likely to have negative health consequences.]]> Wed 11 Apr 2018 11:16:19 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:17382 Wed 11 Apr 2018 11:02:05 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:19199 Wed 11 Apr 2018 10:44:57 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:17958 Wed 11 Apr 2018 09:41:07 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:22756 Wed 11 Apr 2018 09:39:12 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:25066 heme oxygenase-1 expression), inflammation (interleukin-1β (IL-1β) and tumor necrosis factor-α (TNF-α) expression), collagen (COL) and smooth muscle in the lungs; we also assessed lung structure. We quantified macrophages in lung tissue (at P7d) and leukocytes in BALF (at P56d). At P7d, TJ increased pulmonary TAC and COL1α1 expression and attenuated the hyperoxia-induced increase in nitrotyrosine and macrophage influx; however, changes in lung structure were not affected. At P56d, TJ increased TAC, decreased oxidative stress and reversed the hyperoxia-induced increase in bronchiolar smooth muscle. Additionally, TJ alone decreased IL-1β expression, but following hyperoxia TJ increased TNF-α expression and did not alter the hyperoxia-induced increase in leukocyte number. We conclude that TJ supplementation during and after neonatal exposure to hyperoxia protects the lung from some but not all aspects of hyperoxia-induced injury, but may also have adverse side-effects. The effects of TJ are likely due to elevation of circulating antioxidant concentrations.]]> Wed 11 Apr 2018 09:21:28 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:24433 Wed 09 Feb 2022 15:59:14 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:43015 Wed 09 Aug 2023 12:26:25 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:30679 n = 17; age 10.7 (2.4) years) and without asthma (n = 17; age 10.8 (2.3) years), referred for overnight polysomnography, underwent measurement of lung function, plasma appetite hormones, dietary intake and food cravings, activity, and daytime sleepiness. Sleep latency (56.6 (25.5) vs. 40.9 (16.9) min, p = 0.042) and plasma triglycerides (1.0 (0.8, 1.2) vs. 0.7 (0.7, 0.8) mmol/L, p = 0.013) were significantly greater in asthmatic versus non-asthmatic children. No group difference was observed in appetite hormones, dietary intake, or activity levels (p > 0.05). Sleep duration paralleled overall diet quality (r = 0.36, p = 0.04), whilst daytime sleepiness paralleled plasma lipids (r = 0.61, p =0.001) and sedentary time (r = 0.39, p = 0.02). Disturbances in sleep quality and plasma triglycerides were evident in non-obese asthmatic children referred for polysomnography, versus non-asthmatic children. Observed associations between diet quality, sedentary behavior, and metabolic and sleep-related outcomes warrant further investigation, particularly the long-term health implications.]]> Wed 02 Oct 2019 10:15:41 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:44806 Wed 01 May 2024 12:05:04 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:49760 Tue 30 May 2023 18:39:10 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:54436 Tue 27 Feb 2024 13:49:20 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:36521 Tue 26 May 2020 10:11:49 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:39820 Tue 26 Jul 2022 11:33:21 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:44917 P <0.001). In conclusion, the consumption of fast foods, particularly hamburgers, correlates to asthma in a dose-response pattern, which needs to be further validated in longitudinal and interventional studies.]]> Tue 25 Oct 2022 09:17:17 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:54391 Tue 20 Feb 2024 21:00:19 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:54318 Tue 20 Feb 2024 15:51:10 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:38233 Tue 17 Aug 2021 08:35:47 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:41168 Tue 15 Aug 2023 14:44:00 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:45541 2) to investigate effects of fish oil (2000 mg docosahexaenoic acid + 400 mg eicosapentaenoic acid/day), curcumin (160 mg/day) or a combination of both on cerebrovascular function (measured by Transcranial Doppler ultrasound), systemic vascular function (blood pressure, heart rate and arterial compliance) and cardiometabolic (fasting glucose and blood lipids) and inflammatory (C-reactive protein) biomarkers. The primary outcome, cerebrovascular responsiveness to hypercapnia, was not affected by the interventions. However, cerebral artery stiffness was significantly reduced in males following fish oil supplementation (P = 0.007). Furthermore, fish oil reduced heart rate (P = 0.038) and serum triglycerides (P = 0.006) and increased HDL cholesterol (P = 0.002). Curcumin did not significantly affect these outcomes either alone or in combination with fish oil. Conclusion: Regular supplementation with fish oil but not curcumin improved biomarkers of cardiovascular and cerebrovascular function. The combined supplementation did not result in additional benefits. Further studies are warranted to identify an efficacious curcumin dose and to characterize (in terms of sex, BMI, cardiovascular and metabolic risk factors) populations whose cerebrovascular and cognitive functions might benefit from either intervention. Clinical trial registration: ACTRN12616000732482p.]]> Tue 14 Nov 2023 14:41:26 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:52374 Tue 10 Oct 2023 14:37:55 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:557 Thu 25 Jul 2013 09:10:39 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:652 Thu 25 Jul 2013 09:10:28 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:50862 Thu 17 Aug 2023 11:36:01 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:34467 -1.min^-1) underwent a clinical evaluation of known risk factors by a physician and comprehensive laboratory analysis of immune responses both at rest and after two cycling ergometer tests: 60 min at 65% VO₂max (LONG); and 6 x 3 min intervals at 90% VO₂max (INTENSE). Blood tests were performed to determine Epstein Barr virus (EBV) status and DNA was genotyped for a panel of cytokine gene polymorphisms. Saliva was collected for measurement of IgA and detection of EBV DNA. Athletes were then followed for 9 months for self-reported episodes of respiratory illness, with confirmation of the underlying cause by a sports physician. There were no associations with risk of respiratory illness identified for any parameter assessed in the clinical evaluations. The laboratory parameters associated with an increased risk of respiratory illnesses in highly-trained athletes were cytokine gene polymorphisms for the high expression of IL-6 and IFN-γ expression of EBV-DNA in saliva; and low levels of salivary IgA concentration. A genetic risk score was developed for the cumulative number of minor alleles for the cytokines evaluated. Athletes prone to recurrent respiratory illness were more likely to have immune disturbances that allow viral reactivation, and a genetic predisposition to pro-inflammatory cytokine responses to intense exercise.]]> Thu 14 Mar 2019 16:50:14 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:32882 0.05) after adjustment for pretreatment values, treatment period, and treatment order. Similarly, no differences were observed between treatments for arterial stiffness measures (P > 0.05). Conclusion: Increased intake of nitrate-rich vegetables did not lower blood pressure in prehypertensive or untreated grade 1 hypertensive individuals when compared with increased intake of nitrate-poor vegetables and no increase in vegetables.]]> Thu 13 Oct 2022 17:10:46 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:32707 Thu 12 Jul 2018 11:51:23 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:33083 Thu 03 Feb 2022 12:19:51 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:50719 Thu 03 Aug 2023 09:12:38 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:7532 Sat 24 Mar 2018 08:38:27 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:7533 Sat 24 Mar 2018 08:38:26 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:8053 Sat 24 Mar 2018 08:35:04 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:2922 Sat 24 Mar 2018 08:32:17 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:1145 Sat 24 Mar 2018 08:32:05 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:1603 Sat 24 Mar 2018 08:30:39 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:1373 Sat 24 Mar 2018 08:28:19 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:1803 Sat 24 Mar 2018 08:27:33 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:14522 Sat 24 Mar 2018 08:19:45 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:14509 Sat 24 Mar 2018 08:19:42 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:12974 Sat 24 Mar 2018 08:16:09 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:12329 Sat 24 Mar 2018 08:11:37 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:10730 Sat 24 Mar 2018 08:09:49 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:16925 Sat 24 Mar 2018 08:00:30 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:16994 Sat 24 Mar 2018 08:00:13 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:17933 Sat 24 Mar 2018 07:56:33 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:20302 Sat 24 Mar 2018 07:55:12 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:19687 Sat 24 Mar 2018 07:53:51 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:16937 Sat 24 Mar 2018 07:51:50 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:19996 Sat 24 Mar 2018 07:50:48 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:26873 Sat 24 Mar 2018 07:41:42 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:29906 P=0.42) and vegetable (P=0.17) intakes between HCFV and LCFV groups. Dietary alpha carotene, beta carotene, lutein, and beta cryptoxanthin intakes were significantly different between the two groups (P<0.01). Following HCFV there was a significantly greater increase in skin yellowness (b*) in both sun-exposed (P<0.001) and unexposed areas, (P<0.001), with no change in skin lightness (L*) or redness (a*). Significantly higher plasma alpha carotene (P=0.004), beta carotene (P=0.001), and lutein (P=0.028) concentrations were found following the HCFV intervention. Skin yellowness correlated with alpha carotene and beta carotene. Conclusions: Skin yellowness (b*) and fasting plasma carotenoid concentrations were significantly higher following HCFV than LCFV over 4 weeks.]]> Sat 24 Mar 2018 07:40:58 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:27246 Sat 24 Mar 2018 07:29:11 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:26767 Sat 24 Mar 2018 07:24:45 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:4852 Sat 24 Mar 2018 07:18:52 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:4850 Sat 24 Mar 2018 07:18:52 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:22886 Sat 24 Mar 2018 07:15:19 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:23310 Sat 24 Mar 2018 07:13:31 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:24600 Sat 24 Mar 2018 07:11:49 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:48173 Sat 11 Mar 2023 12:23:34 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:47536 Mon 23 Jan 2023 12:22:36 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:46219 Mon 14 Nov 2022 12:04:55 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:35650 Mon 13 Nov 2023 11:04:35 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:48274 Mon 13 Mar 2023 18:53:32 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:53538 Mon 04 Dec 2023 15:44:36 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:29922 Fri 24 Aug 2018 09:03:14 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:34249 Fri 22 Feb 2019 16:55:30 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:23240 Fri 22 Apr 2022 10:21:16 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:37059 Fri 21 Aug 2020 11:53:43 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:17857 Fri 19 Jun 2015 15:04:57 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:53130 Fri 17 Nov 2023 11:58:06 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:46107 −2) versus healthy-weight (BMI <25 kg·m⁻²) subjects with asthma. Design Databases including CINAHL (Cumulative Index to Nursing and Allied Health Literature), Cochrane, Embase and MEDLINE were searched up to July 2019 for English-language studies that recorded medication use or dose in obese and healthy-weight adults with asthma. A critical appraisal checklist was utilised for scrutinising methodological quality of eligible studies. Meta-analysis was performed and heterogeneity was examined with the use of the Chi-squared test. This review was conducted based on a published protocol (www.crd.york.ac.uk/PROSPERO CRD42020148671). Results Meta-analysis showed that obese subjects are more likely to use asthma medications, including short-acting β2-agonists (OR 1.75, 95% CI 1.17–2.60; p=0.006, I²=41%) and maintenance oral corticosteroids (OR 1.86, 95% CI 1.49–2.31; p<0.001, I2=0%) compared to healthy-weight subjects. Inhaled corticosteroid (ICS) dose (µg·day⁻¹) was significantly higher in obese subjects (mean difference 208.14, 95% CI 107.01–309.27; p<0.001, I²=74%). Forced expiratory volume in 1 s (FEV₁) % predicted was significantly lower in obese subjects (mean difference −5.32%, 95% CI −6.75–−3.89; p<0.001, I²=42%); however, no significant differences were observed in FEV₁/forced vital capacity (FVC) ratio between groups. Conclusions We found that obese subjects with asthma have higher use of all included asthma medication classes and higher ICS doses than healthy-weight asthma subjects, despite lower FEV₁ and a similar FEV₁/FVC %. A better understanding of the factors driving increased medication use is required to improve outcomes in this subgroup of asthmatics.]]> Fri 11 Nov 2022 15:35:55 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:22673 Fri 11 Jun 2021 13:31:32 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:30780 Fri 03 Dec 2021 10:34:35 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:24548 Fri 03 Dec 2021 10:34:24 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:32830 Fri 03 Dec 2021 10:34:06 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:37118 Fri 03 Dec 2021 10:32:20 AEDT ]]>